World Pharmaceutical Frontiers’ Post

In this on-demand webinar, explore strategies to master GLP-1 production, along with proven and robust technologies tailored for peptide therapeutics with a focus on GLP-1. Watch now: https://sar.to/ym8ad #SimplifyingProgress #InThisTogether #GLP1

Our very own Associate Director of CMC, Ashley Taylor, highlighted this article by LifeTein.com on the benefits of stapled peptides. Stapled peptides are breaking new ground in drug development, offering enhanced stability and efficacy for targeting previously undruggable interactions. What are your thoughts on the future of peptide therapeutics? Check out the article and let us know! https://lnkd.in/embS6_di #BiotechInnovation #PeptideTherapeutics #DrugDevelopment

With the Biopharma industry starting to build a stronger understanding around the needs and assessments of their mRNA therapeutics, one of the biggest impacts that have been uncovered is the importance of Poly(A) tail length determination and how it effects efficiency and stability of your final product. In the technote below, the SCIEX tech team has developed a simplified workflow for Poly(A) tail analysis to achieve single base resolution for accurate sizing determination on our PA800 plus system. Take a look at this outstanding workflow for a valuable CQA in mRNA assessment! #SCIEX #CE #biopharma #pharma #biotechnology #mRNA #RNA

In Exonoid, we have effectively isolated "red (cardinal) grape" exosomes with high yield and quality, profiling over 150 metabolites using GC-MS/LC-MS analyses. Among these metabolites, a noteworthy compound is "resveratrol," recognized for its potent antioxidant properties and widely utilized in various cosmetic serums. Furthermore, a study on stability and storage conditions has established the optimal parameters for the preservation of these exosomes. As highlighted in the previous post, grape exosomes exhibit considerable potential for application in both the cosmetic and pharmaceutical sectors, with the conducted preclinical and clinical studies reinforcing their significance in this regard.

Empowering Routine Monitoring for DNA/mRNA Therapeutics in QC Labs Gene therapy innovations require reliable monitoring to ensure efficacy and safeguard patient safety. Conventional size-exclusion chromatography (SEC) struggles with large mRNA molecules and unwanted analyte interactions, often impacting chromatographic resolution. In the latest application note from Waters, their scientists showcase the new Alliance iS Bio HPLC System with MaxPeak High-Performance Surfaces (HPS) Technology. This bioinert system provides the dispersion and resolution essential for analyzing biopharmaceutical variants in routine quality control, meeting the evolving needs of therapeutic advancements. Explore how this breakthrough can support your lab's success in DNA/mRNA monitoring.

Monitoring mRNA quality indicators is critical to maintaining product efficacy and patient safety. In this study, the Alliance iS Bio HPLC System was evaluated on its ability to support manufacturing labs in the routine analysis of mRNA therapeutics. Read the application note to see how your new ally for bioseparations is the ideal solution for monitoring new modalities in QC environments. https://bit.ly/4h3hrLT

Join our webinar tomorrow at 11 am EST to learn about recent advancements in peptide drug discovery, including the evolution of mRNA display and peptide DNA-encoded library (DEL) technology for hit generation and selection, as well as novel cyclization techniques and their combinations for peptide conformational rigidity. This webinar will provide a comprehensive perspective on strategies that are crucial for achieving the desired binding affinity and efficacy for developing potent and orally available peptide drugs. Don’t miss your chance to ask questions to our experts! Please register here: https://hubs.li/Q02NVW9F0 #Peptide #DrugDiscovery #mRNA #DELTechnology #PeptideTherapeutics #OralPeptideDrugs #DMPK

Don’t miss the scientific insights of our own William Boomershine, Ph.D. in his exclusive article in The Medicine Maker, Navigating the Analytical Complexity of Oligonucleotide Therapeutics. In it, he shares how to overcome the analytical complexities inherent to oligonucleotide manufacturing, which can unlock untold health benefits of valuable new patient therapies and vaccines. Read the full article ➡️ https://hubs.li/Q02Rvgcb0 #Alcami #TheMedicineMaker #Oligonucleotides #biopharma #pharma #AskAlcami

Targeted protein degraders (TPDs), such as PROTACs and certain molecular glues, have garnered increasing attention in late-stage research and clinical trials recently. Kymera Therapeutics is slated to unveil interim phase 1 results of their STAT3 degrader, KT-333, during the Late-Breaking Research Poster session at the upcoming AACR 2024 conference (April 5-10) in San Diego. Check link for more detail: https://www.aacr.org While most of TPD are small molecules, there's a growing buzz surrounding Degrader-antibody conjugates (DACs) in recent times. Orum Therapeutics’s ORM-6151, a phase 1 stage anti-CD33 antibody-enabled GSPT1 degrader, has recently been acquired by Bristol Myers Squibb. Firefly Bio and Nurix Therapeutics also have their own DACs in development.   Additionally, the 2024 Annual Conference of our society, featuring numerous novel modalities of biologics, will convene in Cambridge, MA, USA on Saturday, May 11, 2024. Registration for the conference is now open via the following link. https://lnkd.in/ecmFPA4v #antibodydiscovery #antibodydrugconjugates #annualmeeting #annualconference #aacr #targetedproteindegrader #degraderantibodyconjugates